Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

NCT ID: NCT00001133

Last Updated: 2021-11-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2006-08-31

Brief Summary

In this study, the protease inhibitors indinavir (IDV) and ritonavir (RTV) will be studied in patients who have high levels of virus while taking other protease inhibitors. The purpose of this study is to see how the body takes in, distributes, and gets rid of IDV and RTV. This study will also look at any side effects that IDV or RTV causes.

IDV is an effective anti-HIV drug, but it can be difficult for patients to take. For IDV to work against HIV, it must be taken 3 times a day at a high dose and with a certain diet. Doctors believe IDV may be easier to take if it is given with RTV. Patients who take IDV and RTV together may be able to take IDV only twice a day and at a lower dose. This study will gather information about the safety and side effects of using IDV and RTV together.

Detailed Description

IDV, a protease inhibitor, has shown excellent clinical and virologic responses when combined with 2 nucleoside analogues. Although effective, the pharmacokinetics of IDV make it difficult to use in many patients. The drug has a short half-life and requires administration in high doses every 8 hours with significant dietary restrictions. Research has shown that IDV kinetics can be improved significantly by the addition of RTV, allowing for administration of IDV at lower doses every 12 hours. The half-life of IDV is prolonged 3- to 5-fold when administered with RTV. Based on these results, it is reasonable to study this combination as a twice-daily dosing regimen.

Patients are randomized to receive 1 of 2 doses of IDV/RTV for 24 weeks (Arms A and B). All patients also receive 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs are not provided by the study. Clinical assessments take place at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 which includes a virology assessment. [AS PER AMENDMENT 4/21/00: Patients who experience a confirmed virologic failure (defined in protocol) and elect to remain on study treatment, are followed through Week 24. Patients who experience a confirmed virologic failure and elect to discontinue study treatment will have a final evaluation at the time of treatment discontinuation.] Patients are hospitalized for 12 hours at the Week 2 study visit for an intensive pharmacokinetic analysis.

Conditions

HIV Infections

Keywords

Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Protease Inhibitors; Ritonavir; Indinavir; Anti-HIV Agents; Pharmacokinetics; Treatment Experienced

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Indinavir sulfate

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are HIV-positive.
• Are at least 18 years old.
• Have a viral load (level of HIV in the blood) of at least 500 copies/ml but no more than 100,000 copies/ml within 45 days of study entry.
• Have been taking the following anti-HIV drug combination for at least 12 weeks before study entry: 2 NRTIs plus amprenavir (APV), nelfinavir (NFV), saquinavir (SQV), or NFV plus SQV.
• Are naive to at least 1 NRTI. This means that there is at least 1 NRTI that the patient has not taken for more than 14 days. In the case of lamivudine (3TC), naive means that the patient has never taken this drug.
• Are willing and able to drink 1.5 liters (a little over 1.5 quarts) of water or other fluids a day.
• Agree to use an effective barrier method of birth control (such as condoms) during the study and for 3 months after.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have taken protease inhibitors other than APV, NFV, SQV, or NFV plus SQV.
• Are resistant to the effects of IDV or RTV, as shown by a blood test. (Patients whose viral load is between 500 and 1,000 copies/ml will not need to be tested.)
• Have any active opportunistic (AIDS-related) infection in the 14 days before study entry.
• Have any medical condition or history of disease that would prevent them from completing the study or put them at risk.
• Have cancer that requires chemotherapy.
• Have an active infection that requires treatment in the 14 days before study entry.
• Have a fever for a week or more in the 30 days before study entry.
• Have taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the 30 days before study entry.
• Have received a vaccine in the 21 days before study entry.
• Have received an experimental drug or a drug that affects the immune system in the 30 days before study entry.
• Have taken or plan to take certain other medications that may affect the study.
• Are pregnant or breast-feeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John G. Gerber

Role: STUDY_CHAIR

Edward P. Acosta

Role: STUDY_CHAIR

Locations

Alabama Therapeutics CRS

Birmingham, Alabama, United States

USC CRS

Los Angeles, California, United States

Ucsf Aids Crs

San Francisco, California, United States

Johns Hopkins Adult AIDS CRS

Baltimore, Maryland, United States

NY Univ. HIV/AIDS CRS

New York, New York, United States

Univ. of Cincinnati CRS

Cincinnati, Ohio, United States

Pitt CRS

Pittsburgh, Pennsylvania, United States

Countries

Puerto Rico; United States

References

Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG; Adult AIDS Clinical Trials Group 5055 Protocol Team. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-66. doi: 10.1097/00126334-200411010-00004.

Reference Type: RESULT

PMID: 15483465 (View on PubMed)

King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS. 2005 Jul 1;19(10):1059-63. doi: 10.1097/01.aids.0000174452.78497.54.

Reference Type: RESULT

PMID: 15958837 (View on PubMed)

Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):399-419. doi: 10.1007/s10928-006-9006-4. Epub 2006 Apr 1.

Reference Type: RESULT

PMID: 16583266 (View on PubMed)

Other Identifiers

10672

Identifier Type: REGISTRY

Identifier Source: secondary_id

ACTG A5055

Identifier Type: -

Identifier Source: secondary_id

AACTG A5055

Identifier Type: -

Identifier Source: secondary_id

A5055

Identifier Type: -

Identifier Source: org_study_id